Last reviewed · How we verify
Azithromycin / Ribaroxaban / Paracetamol
This is a fixed-dose combination of three drugs: azithromycin (a macrolide antibiotic), rivaroxaban (an anticoagulant), and paracetamol (an analgesic/antipyretic) that work through distinct mechanisms.
This is a fixed-dose combination of three drugs: azithromycin (a macrolide antibiotic), rivaroxaban (an anticoagulant), and paracetamol (an analgesic/antipyretic) that work through distinct mechanisms. Used for Infection with concurrent thrombotic risk requiring anticoagulation and symptom management (indication not clearly defined in public literature).
At a glance
| Generic name | Azithromycin / Ribaroxaban / Paracetamol |
|---|---|
| Also known as | without Ivermectin |
| Sponsor | Gilberto Cruz Arteaga |
| Drug class | Fixed-dose combination (macrolide antibiotic / anticoagulant / analgesic) |
| Target | Bacterial 50S ribosome (azithromycin); Factor Xa (rivaroxaban); COX enzymes (paracetamol) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Cardiovascular / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Rivaroxaban is a direct Factor Xa inhibitor that prevents thrombin generation and blood clot formation. Paracetamol inhibits prostaglandin synthesis in the central nervous system, reducing pain and fever. The combination addresses infection, thrombotic risk, and symptom management simultaneously.
Approved indications
- Infection with concurrent thrombotic risk requiring anticoagulation and symptom management (indication not clearly defined in public literature)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea)
- Bleeding (rivaroxaban-related)
- Hepatotoxicity (paracetamol-related)
- QT prolongation (azithromycin-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: